AU2023202177A1 - Pharmaceutical for treating novel coronavirus infection - Google Patents
Pharmaceutical for treating novel coronavirus infection Download PDFInfo
- Publication number
- AU2023202177A1 AU2023202177A1 AU2023202177A AU2023202177A AU2023202177A1 AU 2023202177 A1 AU2023202177 A1 AU 2023202177A1 AU 2023202177 A AU2023202177 A AU 2023202177A AU 2023202177 A AU2023202177 A AU 2023202177A AU 2023202177 A1 AU2023202177 A1 AU 2023202177A1
- Authority
- AU
- Australia
- Prior art keywords
- cov
- sars
- day
- covid
- symptoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (13)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022-006725 | 2022-01-19 | ||
| JP2022006725 | 2022-01-19 | ||
| JP2022-012386 | 2022-01-28 | ||
| JP2022012386 | 2022-01-28 | ||
| JP2022017132 | 2022-02-07 | ||
| JP2022-017132 | 2022-02-07 | ||
| JP2022027629 | 2022-02-25 | ||
| JP2022-027629 | 2022-02-25 | ||
| JP2022120325 | 2022-07-28 | ||
| JP2022-120325 | 2022-07-28 | ||
| JP2022-149666 | 2022-09-21 | ||
| JP2022149666 | 2022-09-21 | ||
| PCT/JP2023/001243 WO2023054732A2 (ja) | 2022-01-19 | 2023-01-18 | 新型コロナウイルス感染症治療用医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023202177A1 true AU2023202177A1 (en) | 2024-07-18 |
Family
ID=85780780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023202177A Pending AU2023202177A1 (en) | 2022-01-19 | 2023-01-18 | Pharmaceutical for treating novel coronavirus infection |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250099474A1 (https=) |
| EP (1) | EP4467142A4 (https=) |
| JP (2) | JP7273455B1 (https=) |
| KR (1) | KR20240137021A (https=) |
| AU (1) | AU2023202177A1 (https=) |
| MX (1) | MX2024008910A (https=) |
| WO (1) | WO2023054732A2 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL300412A (en) | 2020-08-24 | 2023-04-01 | Gilead Sciences Inc | Phospholipid compounds and their uses |
| TW202344257A (zh) | 2020-10-16 | 2023-11-16 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| LT4122926T (lt) | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
| WO2024031089A1 (en) | 2022-08-05 | 2024-02-08 | Gilead Sciences, Inc. | Sars-cov2 main protease inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036410A1 (en) * | 1998-01-13 | 1999-07-22 | Scriptgen Pharmaceuticals, Inc. | Triazine antiviral compounds |
| PL2399910T3 (pl) * | 2009-02-13 | 2014-09-30 | Shionogi & Co | Pochodne triazyny jako antagoniści receptora p2x3 i/albo p2x2/3 i kompozycja farmaceutyczna zawierająca je |
| CN103153968B (zh) | 2010-08-10 | 2016-02-03 | 盐野义制药株式会社 | 三唑衍生物及含有其的具有镇痛作用的药物组合物 |
| JP6075621B2 (ja) | 2010-08-10 | 2017-02-08 | 塩野義製薬株式会社 | 新規複素環誘導体およびそれらを含有する医薬組成物 |
| TW201331188A (zh) | 2011-12-15 | 2013-08-01 | Shionogi & Co | 經取代之三□衍生物及含有其之醫藥組成物 |
| WO2013118855A1 (ja) | 2012-02-09 | 2013-08-15 | 塩野義製薬株式会社 | 複素環および炭素環誘導体 |
| TWI637949B (zh) | 2013-06-14 | 2018-10-11 | 塩野義製藥股份有限公司 | 胺基三衍生物及含有其等之醫藥組合物 |
| WO2019087884A1 (ja) * | 2017-10-31 | 2019-05-09 | 富士フイルム株式会社 | 組成物、抗菌組成物、抗ウイルス用組成物、抗ノロウイルス用組成物、スプレー、ワイパー |
| EP4282420A4 (en) * | 2021-01-20 | 2024-11-27 | National University Corporation Hokkaido University | ANTIVIRAL AGENT |
| EP4313097A4 (en) * | 2021-03-29 | 2025-03-19 | Shireen Nature Company for General Trading, Ltd. | Willow extract and its use in treating coronavirus infection, inflammation, and associated medical conditions |
| LT4122926T (lt) * | 2021-04-14 | 2025-07-25 | Shionogi & Co., Ltd. | Triazino dariniai, turintys virusų replikaciją slopinantį poveikį, ir juos apimanti farmacinė kompozicija |
| AU2022353486A1 (en) * | 2021-09-28 | 2024-05-02 | National University Corporation Hokkaido University | Pharmaceutical composition containing triazine derivative |
| EP4289432A4 (en) * | 2021-11-24 | 2025-01-15 | Shionogi & Co., Ltd | PREPARATION FOR ORAL ADMINISTRATION CONTAINING TRIAZINE DERIVATIVES |
-
2023
- 2023-01-18 WO PCT/JP2023/001243 patent/WO2023054732A2/ja not_active Ceased
- 2023-01-18 US US18/729,630 patent/US20250099474A1/en active Pending
- 2023-01-18 AU AU2023202177A patent/AU2023202177A1/en active Pending
- 2023-01-18 MX MX2024008910A patent/MX2024008910A/es unknown
- 2023-01-18 KR KR1020247027109A patent/KR20240137021A/ko active Pending
- 2023-01-18 EP EP23714052.0A patent/EP4467142A4/en active Pending
- 2023-01-18 JP JP2023511553A patent/JP7273455B1/ja active Active
- 2023-04-26 JP JP2023072576A patent/JP2023105826A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7273455B1 (ja) | 2023-05-15 |
| WO2023054732A3 (ja) | 2023-06-15 |
| KR20240137021A (ko) | 2024-09-19 |
| TW202339757A (zh) | 2023-10-16 |
| US20250099474A1 (en) | 2025-03-27 |
| EP4467142A2 (en) | 2024-11-27 |
| JPWO2023054732A1 (https=) | 2023-04-06 |
| JP2023105826A (ja) | 2023-07-31 |
| MX2024008910A (es) | 2024-07-25 |
| WO2023054732A2 (ja) | 2023-04-06 |
| EP4467142A4 (en) | 2025-12-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250099474A1 (en) | Pharmaceutical for treatment of novel coronavirus infection | |
| TWI815396B (zh) | 具有病毒增殖抑制作用之三嗪衍生物及含有其等之醫藥組合物 | |
| JP7466731B2 (ja) | トリアジン誘導体を含有する経口投与する製剤 | |
| RU2700415C1 (ru) | Ингибиторы репликации вирусов гриппа | |
| TW202320793A (zh) | 含有三嗪衍生物之醫藥組合物 | |
| CN108276278A (zh) | 制备流感病毒复制抑制剂的方法 | |
| US20250127788A1 (en) | Pharmaceutical composition containing triazine derivative | |
| US20250025459A1 (en) | Covid-19 treatment medicine characterized by combining 3cl protease inhibitor and covid-19 treatment drug | |
| CN116514734A (zh) | 三嗪衍生物的制造方法和含有三嗪衍生物的口服给与的制剂 | |
| CN116782904A (zh) | 含有三嗪衍生物的医药组合物 | |
| HK40116243A (en) | Pharmaceutical for treating novel coronavirus infection | |
| TWI916636B (zh) | 新型冠狀病毒感染症治療用醫藥 | |
| CN117120057A (zh) | 新型冠状病毒传染病治疗用药物 | |
| AU2024307335A1 (en) | Pharmaceutical composition containing uracil derivative | |
| HK40114521A (en) | Pharmaceutical composition containing triazine derivative | |
| WO2024153018A1 (zh) | 螺环化合物的结晶及其制备方法 | |
| KR20250133673A (ko) | 항바이러스 약학적 조성물 및 이의 제조 방법 | |
| CN118766912A (zh) | Sars-cov-2非结构蛋白13（nsp13）解旋酶的小分子抑制剂 |